SCHEMBL10277219

SCHEMBL10277219

Cc1ccc(-c2cn3nc(-c4cccc(C(F)(F)F)n4)ccc3n2)cc1NC(=O)c1cccc(/C=C/C(=O)O)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 5/20 0.39
CSF1R P07333 4/20 0.39
CSNK1D P48730 5/20 0.39
CSNK1E P49674 5/20 0.39
GAA P10253 2/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
GLA P06280 1/20 0.39
POLB P06746 1/20 0.38
ITGB3 P05106 2/20 0.38
ITGAV P06756 2/20 0.38
ITGA2B P08514 2/20 0.38
TTK P33981 1/20 0.37
BRAF P15056 4/20 0.37
LDLR P01130 1/20 0.36
PCSK9 Q8NBP7 1/20 0.36
MAPK13 O15264 1/20 0.36
LYN P07948 1/20 0.36
PDGFRA P16234 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10277221 1.00 KIT (0.39) KITCSF1RCSNK1DCSNK1EGAA
SCHEMBL10276930 0.92 POLB (0.38) KITCSF1RCSNK1DCSNK1EGAA
SCHEMBL10276929 0.87 EPHX2 (0.42) KITCSF1RCSNK1DCSNK1EGAA
SCHEMBL10276935 0.87 EPHX2 (0.42) KITCSF1RCSNK1DCSNK1EGAA
SCHEMBL10277392 0.85 ALDH1A1 (0.42) KITCSNK1DCSNK1EGAAKDM4E
SCHEMBL10277391 0.85 ALDH1A1 (0.42) KITCSNK1DCSNK1EGAAKDM4E
SCHEMBL10276933 0.85 CSF1R (0.40) KITCSF1RCSNK1DCSNK1EGAA
SCHEMBL10277153 0.82 CSNK1D (0.40) KITCSNK1DCSNK1EGAAKDM4E
SCHEMBL10277152 0.82 CSNK1D (0.40) KITCSNK1DCSNK1EGAAKDM4E
SCHEMBL9956235 0.82 CSNK1D (0.42) CSNK1DCSNK1EBRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2635578-B1 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES HENGRUI USA LTD (US) 2015-12-16 EP disclosed
US-8871767-B2 2-arylimidazo[1,2-B]pyridazine, 2-phenylimidazo[1,2-A]pyridine, and 2-phenylimidazo[1,2-A]pyrazine derivatives HENGRUI (USA) LTD. (US) 2014-10-28 US disclosed
US-20120178751-A1 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES HENGRUI (USA), LTD. 2012-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178751-A1 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES PRXL2A, CDK2, CCNA2 KIT 2117/4885CSF1R 2960/4885CSNK1D 655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.